Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 54

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 54
---
 an independent transaction
committee of the Board (the “Transaction Committee”) to oversee a thorough strategic review process, with the assistance of representatives of Stikeman Elliott LLP, the Company’s Canadian counsel
(“Stikeman”), Cooley LLP, the Company’s U.S. counsel (“Cooley”) and its financial advisor, Leerink Partners LLC (“Leerink Partners”), to explore potential opportunities and strategic
alternatives in light of the Company’s prospects and operations. Following such review and the implementation of a robust and broad sales process which did not yield any compelling proposals, as more fully described below, the Board, upon
recommendation of the Transaction Committee, determined that it was in the best interest of the Company to enter into the Agreement with Parent for the sale of all of its Common Shares, which would allow for a return of capital to the shareholders
at Closing and the opportunity for continued participation in milestones and royalties from existing and potential future partnerships. As part of its strategic review, the Company had considered many alternatives, including a voluntary liquidation
of the Company to distribute any available cash to shareholders; however, it was ultimately determined that the Arrangement was the most advantageous transaction for the Company’s stakeholders including its Shareholders.

The first meeting of the Transaction Committee was held on February 27, 2025 and was also attended by members of management and
representatives of Cooley. At this meeting, each of the Transaction Committee members confirmed that they were willing and able to act as members of the Transaction Committee and each accepted their appointment. The Transaction Committee considered
the need for a financial advisor to assist the Transaction Committee in discharging its mandate and agreed to consider the available options with management and make a decision on which financial advisor to retain at a subsequent Transaction
Committee meeting.

Following the formation of the Transaction Committee, in addition to the meetings held by the Transaction Committee as
further described below, the Company’s management regularly provided updates to the Transaction Committee regarding potential strategic transactions and the status of the various discussions between the Company and potential counterparties,
and the Transaction Committee provided input to the Company’s management.

In addition, the Board was regularly informed as to the
status of the Company’s efforts to wind-down clinical programs and cease pre-clinical work in an effort to preserve cash, including workforce and other cost reductions, which initiatives were further
described in the Company’s public filings on January 9, 2025, March 3, 2025 and March 31, 2025.

On